Embecta Corp. (EMBC)
NASDAQ: EMBC · Real-Time Price · USD
3.320
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
3.330
+0.010 (0.30%)
After-hours: May 22, 2026, 7:30 PM EDT
Embecta Revenue
Embecta had revenue of $221.80M in the quarter ending March 31, 2026, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $1.04B, down -3.43% year-over-year. In the fiscal year ending September 30, 2025, Embecta had annual revenue of $1.08B, down -3.80%.
Revenue (ttm)
$1.04B
Revenue Growth
-3.43%
P/S Ratio
0.19
Revenue / Employee
$563,514
Employees
1,850
Market Cap
196.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.08B | -42.70M | -3.80% |
| Sep 30, 2024 | 1.12B | 2.30M | 0.21% |
| Sep 30, 2023 | 1.12B | -8.70M | -0.77% |
| Sep 30, 2022 | 1.13B | -35.80M | -3.07% |
| Sep 30, 2021 | 1.17B | 79.80M | 7.35% |
| Sep 30, 2020 | 1.09B | -23.50M | -2.12% |
| Sep 30, 2019 | 1.11B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AngioDynamics | 313.73M |
| OraSure Technologies | 113.02M |
| Sanara MedTech | 107.48M |
| Pro-Dex | 74.64M |
| KORU Medical Systems | 43.26M |
| Utah Medical Products | 37.53M |
| Stereotaxis | 31.20M |
| Nyxoah | 17.67M |
EMBC News
- 7 days ago - Embecta price target lowered to $3 from $11 at BofA - TheFly
- 9 days ago - Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification - MarketBeat
- 10 days ago - embecta Completes Acquisition of Owen Mumford Holdings Limited - GlobeNewsWire
- 11 days ago - Embecta Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 17 days ago - embecta to Participate at the 2026 BofA Securities Global Health Care Conference - GlobeNewsWire
- 18 days ago - Embecta price target lowered to $5 from $12 at Mizuho - TheFly
- 19 days ago - Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 20 days ago - Embecta Earnings Call Transcript: Q2 2026 - Transcripts